Genedrive (GDR) , a molecular diagnostics company, announced an initial order for its CYP2C19-ID test kit for stroke treatment selection, to support an implementation assessment at Greater Manchester's Comprehensive Stroke Centre (CSC).
Genedrive's CYP2C19 ID kit is a molecular point-of-care test for rapid CYP2C19 genotyping, used to identify which patients may or may not respond to blood clot prevention drugs (eg clopidogrel) following ischaemic stroke. The UK's National Institute for Health and Care Excellence (NICE) recently published guidance that CYP2C19 genotyping should be used to guide clopidogrel use after ischaemic stroke or transient ischaemic attack, and as the test of choice for point-of-care strategies.
The Greater Manchester CSC is the largest and busiest hyperacute stroke unit in England with more than 2,000 stroke patient admissions per year, and is situated within the Manchester Centre for Clinical Neurosciences (MCCN) at Salford Royal Hospital, part of Northern Care Alliance NHS Foundation Trust. The implementation assessment's aim is to establish the benefit for patients across Greater Manchester.
Dr Gino Miele, CEO of Genedrive, commenting: "With recent NICE guidance recommending CYP2C19 genotyping strategies in the UK NHS for IS and TIA patients in the NHS who are eligible for receiving the antiplatelet Clopidogrel, and recommending our test as the point-of-care platform of choice, these initial first-sales of our CYP2C19 ID-kit in the UK to one of the largest stroke centres nationally is a key initial milestone in our CYP2C19 commercialisation strategy, and further strengthens our pharmacogenetic positioning strategy in emergency care more broadly. We look forward to increasing implementation of our CYP2C19 test in the UK NHS and internationally to the benefit of both healthcare systems financially and improvement of patient outcomes."
View from Vox
Genedrive marks a significant milestone with the first commercial order for its CYP2C19-ID pharmacogenetic test for stroke treatment selection. The initial order is worth c. £0.1m and will serve the largest hyperacute stroke unit in the UK in Greater Manchester, where care typically covers the first 72 hours after admission.
The news comes after the UK's NICE established guidance recommending lab or point-of-care use of CYP2C19 as the platform of choice for the NHS to guide clopidogrel use for ischaemic and transient ischaemic stroke patients. Factoring in potential improvements in patient outcomes in addition to direct healthcare financial savings, implementation of CYP2C19 genotyping has potential value to the NHS of c. £454m over 5 years.
The Greater Manchester CSC is an ideal first customer for GDR's CYP2C19-ID kit, positioning the product for rapid growth and strong initial revenues. Today's news is further testament to Genedrive's effective commercialisation strategy. In its most recent interim results, the company announced solid revenue growth, a much narrowed operating loss, and significant operational progress for its MT-RNR1 and CYP2C19 products.
Follow News & Updates from Genedrive: